Adherence to Onabotulinumtoxina Treatment in Post-Stroke and Multiple Sclerosis Patients with Spasticity from the ASPIRE Study-Adherence to Onabotulinumtoxina Treatment in Post-Stroke and Multiple Sclerosis Patients with Spasticity from the ASPIRE Study

Adherence to Onabotulinumtoxina Treatment in Post-Stroke and Multiple Sclerosis Patients with Spasticity from the ASPIRE Study

Back to course

Video Transcription

Video Summary

The ASPIRE study analyzed the adherence to onabotulinum toxin A treatment in post-stroke and multiple sclerosis patients with spasticity. The study found that the majority of patients were treatment-adherent, with over five treatment sessions on average over a two-year period. Factors that influenced treatment adherence included being treated in the European Union, using orthotic devices, and treating the thumb and palm. In the multiple sclerosis population, factors such as having secondary progressive MS, being naive to botulinum toxin treatment, and having a longer treatment interval were associated with lower adherence. The study emphasizes the need for personalized treatment to optimize spasticity management.

Keywords

ASPIRE study

adherence

onabotulinum toxin A treatment

spasticity management

multiple sclerosis